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Aim: Late-onset Alzheimer’s disease (LOAD) accounts for 95% of all Alzheimer’s cases and 
is genetically complex in nature. Overlapping clinical and neuropathological features 
between AD, FTD and Parkinson’s disease highlight the potential role of genetic pleiotropy 
across diseases. Recent GWAS have uncovered 20 new loci for AD risk, however these 
exhibit small effect sizes. Using NGS, here we perform association analyses using exome-
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Methods: Whole-exome sequencing was performed on 132 AD cases and 53 control 
samples. Exome-wide single variant association and gene burden tests were performed for 
76,640 non-singleton variants. Samples were also screened for known causative mutations 
in familial genes in AD and other dementias. Single variant association and burden analysis 
was also carried out on variants in known AD and other neurologic dementia genes.  
 
Results: Tentative single variant and burden associations were seen in several genes with 
kinase and protease activity. Exome-wide burden analysis also revealed significant burden 
of variants in PILRA (P=3.4x10-5), which has previously been linked to AD via GWAS, hit 
ZCWPW1. Screening for causative mutations in familial AD and other dementia genes 
revealed no pathogenic variants. Variants identified in ABCA7, SLC24A4, CD33 and LRRK2 
were nominally associated with disease (P<0.05) but did not withstand correction for multiple 
testing. APOE (P=0.02) and CLU (P=0.04) variants showed significant burden on AD.  
Conclusions: In addition, polygenic risk scores (PRS) were able to distinguish between 
cases and controls with 83.8% accuracy using 3,268 variants, sex, age at death and APOE 
ε4 and ε2 status as predictors. 
 
Abbreviations 
AD   – Alzheimer’s disease 
AUC  – area under curve 
BDR  – Brains for Dementia Research 
DLB   – Dementia with Lewy bodies 
fEOAD  – familial early onset Alzheimer’s disease 
FTD  – Frontotemporal dementia 
GWAS  – genome-wide association study 
LOAD   – late onset Alzheimer’s disease 
MAF   – minor allele frequency 
NGS   – next generation sequencing 
OR   – odds ratio 
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PCR   – polymerase chain reaction 
PD   – Parkinson’s disease 
PRS   – polygenic risk score 
 
1. Introduction 
Alzheimer's disease (AD) is the most common form of dementia, affecting over 850,000 
people in the UK alone, a number expected to rise to 1 million by 2025 [1]. There are two 
forms distinguished by the age when symptoms first appear. In the early-onset familial form 
(fEOAD), symptoms appear before 65 years of age, however this only accounts for about 
5% of cases [2]. Mutations in the familial genes APP, PSEN1 and PSEN2 are rare but highly 
penetrant. Individuals with these mutations are almost certain to develop fEOAD [3]. The 
majority of cases are sporadic in nature and classified as late-onset (LOAD), with symptoms 
appearing at 65 years or later. This represents the other 95% of all incidences [4]. Presence 
of the APOE ε4 allele is the largest known genetic risk factor for LOAD, with a 2-3 fold 
increase in risk for carriers and 15 fold for individuals homozygous for the ε4 allele [5]. The 
rare ε2 allele confers a protective effect and appears to reduce AD risk by up to 40%. 
Genome-wide association studies (GWAS) have identified 20 risk variants associated with 
LOAD [6–9]; this has implicated several new pathways in AD, such as endocytic processing, 
inflammation and cholesterol transport [8]. Although highly replicable in Caucasian groups, 
these effects have been difficult to replicate in other populations [10]. These common 
variants also exert only small effects on disease risk, which does not account for much of the 
missing heritability in AD. It is likely that low frequency variants, not detected by GWAS, 
could have greater effect sizes and therefore explain more of the heritable component.  
Advances in next-generation sequencing (NGS) in recent years have allowed exomes and 
entire genomes to be explored at single-base level. The exome accounts for approximately 
1% of the human genome, yet it harbours almost 85% of known mutations underlying 
disease-related traits [11]. Therefore, rare mutations can be identified using this technology. 
Whole-exome sequencing (WES) has identified a rare variant in the TREM2 gene, R47H, 
associated with a 5-fold increase in AD risk [12]. These studies have also found rare 
causative variants in CLU and SORL1 that were overlooked by GWAS [13]. By identifying 
the genetic variants of individuals, WES has the potential to uncover more rare variants 
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There are several overlapping clinical and neuropathological features across different 
dementias. For example, dementia with Lewy bodies (DLB) shares clinical features with AD 
and Parkinson’s disease (PD), often resulting in misdiagnosis. PD and DLB are both 
synucleinopathies presenting with alpha-synuclein deposits in the brain, whereas APOE ε4 
increases risk of disease in AD and DLB [14]. This suggests that genetic risk factors may 
contribute to more than one disease, known as genetic pleiotropy, whereby a gene or DNA 
variant can influence multiple phenotypes. 
 
Clinically well-characterised brain tissue samples from healthy individuals remains a limiting 
factor in the study of neurological disorders [15], Brains for Dementia Research (BDR) 
(www.brainsfordementiaresearch.org.uk) is a network of six leading UK brain banks (jointly 
funded by Alzheimer’s Research UK and Alzheimer’s Society), specifically created to 
address the shortages of high-quality brain tissue samples from healthy individuals as well 
as those with dementia.  This project is a planned brain donation programme with over 3000 
participants, aged 65 years and above, with and without the diagnosis of dementia.  Regular, 
standardised cognitive and psychiatric assessment of potential brain donors during life is 
critical in optimising the value of brain tissue for research [16,17]. 
We performed single variant and burden analysis on coding variants to identify significant 
associations with LOAD. We also report on screening of 132 LOAD patients from the Brains 
for Dementia Research (BDR) resource with the aim to identify causative or predicted 
pathogenic coding variants in 40 selected genes. Of these, 16 are associated with familial 
forms of neurodegeneration, including fEOAD (APP, PSEN1 and PSEN2), frontotemporal 
dementia (FTD) and Amyotrophic lateral sclerosis (ALS) (C9or72, CHMP2B, FUS, GRN, 
MAPT, TARDBP and VCP), PD (LRRK2, PARK2, PARK7, PINK1 and SNCA) and Prion 
disease (PRNP). The remaining genes were selected from AD GWAS and NGS (20 GWAS, 
APOE and TREM2).  
Polygenic risk scores (PRS) have been increasingly used to investigate the effect of multiple 
genetic variants on disease traits. It is based on the notion that many variants with small 
effects will not be detectable at genome-wide significance, however collectively they may 
have a strong effect [18]. PRS were generated to examine the association between multiple 
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2. Materials and Methods 
2.1 BDR samples 
The BDR cohort comprised of 132 clinically diagnosed LOAD (age at onset >65 years) 
cases and 53 cognitively normal controls; all diagnoses were neuropathologically confirmed 
(Supplementary Table S1). Neuropathological diagnoses were undertaken by experienced 
neuropathologists within the Brains for Dementia Research network and were based on Thal 
Aβ phases [19],  neurofibrillary tangle Braak stages [20], Consortium to Establish a Registry 
for Alzheimer’s disease (CERAD) criteria for AD [21] which are all combined in the National 
Institute on Aging – Alzheimer’s Association guidelines [22], together with the Newcastle / 
McKeith criteria for Lewy body disease [23] and for FTLD-TDP as described by [24]. Whilst 
there are no fully established criteria for vascular pathology the VCING criteria were used 
[25] along with those proposed by Smallwood et al (2012) [26] and Grinberg and Thal (2010) 
[27]. 
Demographics of case and control samples for each centre are shown in Table 1. The 
average age at death was 82.5 years (range 65-101 years) for LOAD samples. For control 
individuals, average age at death was 85.9 years (range 58-104 years). The proportion of 
females between cases and controls were similar, accounting for around 50% of the total 
sample size. APOE ε4 carriers were 3-fold higher in cases (64.7%) with almost one fifth 
(17.3%) being homozygous for the ε4 allele. In comparison only 24.5% of controls were 
carriers and no individuals were ε4ε4. The ε2 allele was present in 10 control samples 
(18.9%) and 8 cases (6.2%), with both a case and control sample being homozygous for the 
allele. The higher 3-fold frequency observed in control samples correlates with the protective 
effect of the ε2 allele. All samples in the BDR cohort used for analysis were classified as AD 
or control by neuropathology.  
The BDR has a number of neuropathological features available for more definitive analysis 
of genotype-phenotype correlation [28]. Data includes the CERAD scale, Braak tangle and 
Lewy body staging, with simplified measures (present/absent; mild/moderate/severe) of 
small vessel disease, deposition of TDP-43 protein, arteriolar Aβ-CAA and cerebrovascular 
atherosclerosis. Detailed clinical and cognitive information on the samples is also available 
upon request, demonstrating the potential value of the BDR cohort for very detailed analyses 
in future studies as more extensive genetic data is generated.  
2.2 DNA extraction 
DNA was extracted from brain tissue using standard phenol-chloroform procedures. 
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spectrometer to ensure high concentration and quality material was obtained. Samples were 
genotyped for APOE ε2, ε3 and ε4 alleles using the TaqMan method (Applied Biosystems) to 
determine APOE status. 
2.3 Exome sequencing library prep 
DNA libraries were hybridised to exome-capture probes with Agilent SureSelect Human All 
Exon Kit V4 for Illumina GA (Agilent Technologies) as per manufacturer’s protocol. Exome-
enriched libraries were sequenced on the Illumina HiSeq 2500 using 2 x 100bp paired end 
read cycles. The Agilent capture library includes 5’ and 3’ untranslated regions. 
2.4 Bioinformatics 
Paired-end sequence reads were aligned to the human reference genome build 19 (UCSC 
hg19) using Burrows-Wheeler Aligner [29]. Format conversion, indexing and removal of PCR 
duplicates were performed with Picard (www.picard.sourceforge.net/index.shtml). The 
Genome Analysis Toolkit was used for recalibration of base quality scores, realignment 
around indels and variant calling [30]. Variants were annotated using ANNOVAR [31] and 
Variant Effect Predictor [32] predicted SIFT and Polyphen2 scores of protein coding variants. 
Consistency between SIFT and Polyphen2 predictions and the databases allowed more 
reliable classification. Variants were also checked against established databases (dbSNP 
v.149, 1000 Genomes Project and Exome Variant Server).  
2.5 Filtering 
Singleton variants with MAF < 0.002 were removed in VCFtools [33]. Coding variants in 
genes were filtered by annotation with SnpSift [34]. Visualisation of variants was performed, 
when necessary, using Integrative Genomics Viewer [35]. Individuals with a calculated age 
at onset below 65 years were removed and samples were screened for causative mutations 
in fEOAD genes APP, PSEN1 and PSEN2 to ensure only sporadic cases were used for 
analyses. Pathogenicity of variants was determined using pathogenic status in AD&FTD and 
PD mutation databases [36].  
2.6 Association analyses 
Quality control filtering was performed on the VCF using VCFtools. Individuals were 
removed if genotyping rate <97%, followed by markers with call rate <98%. Markers with 
significant deviation (P<0.001) from the Hardy-Weinberg equilibrium in control individuals 
were removed. After removing samples and markers failing quality control, 290 individuals 
remained with 76,640 non-singleton variants in coding regions. The average genotyping rate 
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Plink files were imported to PLINK-SEQ [37] (https://atgu.mgh.harvard.edu/plinkseq/). 
Single-variant association was performed on samples using a logistic regression test 
correcting for the covariates sex, age at death and APOE ε4 allele count. 
Gene-based association for genes of interest was calculated in R using a SKAT-O [38] 
burden test. The C-alpha test was used for exome-wide analysis and the SKAT-O test was 
used for selected genes. 
2.7 Polygenic risk scoring 
PRS were generated for BDR samples using PRSice [39]. The International Genomics of 
Alzheimer’s Project (IGAP) summary data was used as the base dataset, collated from 
17,008 LOAD cases and 37,154 controls. A region of 500kb around the APOE locus was 
excluded from the analysis. The best-fit model with the greatest predictive accuracy was 
computed using area under the curve (AUC) in SPSS. Additional predictor variables included 
were the number of APOE ε4 and ε2 alleles, age, sex and genotypes for the GWAS SNPs. 
3. Results 
3.1 Overview of data 
Exome-sequencing was performed on a total of 292 individuals. The final cohort consisted of 
132 LOAD cases and 53 control samples after quality control filtering. A total of 157,217 
non-singleton variants were present in 290 individuals, with a minimum of 2 alleles observed 
per variant. Filtering to retain only coding mutations resulted in 76,640 variants for exome-
wide analysis. 
3.2 Exome-wide analyses 
Burden analysis using a C-alpha test highlighted some nominally significant gene 
associations with AD, shown in Table 2. PILRA and PRSS45 are just below the Bonferroni-
corrected threshold (P=2x10-6) at P=3.4x10-5 and P=5.9x10-5, respectively. PILRA has 
previously been linked to AD through ZCWPW1, which was highlighted by the GWAS meta-
analysis [9]. Five variants in PILRA contribute to the effect: intronic variants rs7792525, 
rs190071731 and rs148891131, synonymous mutation rs2405442 and missense variant 
p.S279L (rs34266222). GWAS SNP rs1476679 is in weak LD with rs2405442 (R2=0.50). 
This mutation is tolerated as predicted by SIFT and Polyphen2. The other genes have not 
previously been linked to AD. PRSS45 contains 5 variants that drive this signal, of which 2 
were highly associated with disease (Table 3), therefore it is possible that these SNPs are 
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Exome-wide association analysis was performed on the non-singleton variants, correcting 
for age, sex and APOE ε4 status of individuals. As expected, APOE SNP rs429358 showed 
the most significant association prior to adjusting for covariates (P=7.2x10-9, OR=6.5 [3.2-
13.1]). There were no significant associations at the genome-wide threshold (P=5x10-8) or at 
the suggestive threshold (P=1x10-5) after correction. However due to low sample numbers, 
we do not have the power to detect any association at that level. Some tentative 
associations were observed and are shown in Table 3.  
Several of the genes encompassing variants are involved in signaling pathways, including 
serine proteases PRSS42 and PRSS45 and inositol triphosphate receptor ITPR3. SIFT and 
Polyphen2 predictions indicate that most mutations are benign or tolerated. However 
missense mutations TMEM260 p.A245S/T (rs17776256) and AVPR1B p.K65N (rs35369693) 
were predicted to be probably damaging by both software. Both variants are more frequent 
in control samples, signifying a protective effect. MEP1B is a metalloprotease recently 
implicated in APP cleavage and has been implicated in inflammation. The synonymous 
variant p.S537 (rs173032) has an odds ratio of 3.1 (1.6-5.9) and has a significantly greater 
frequency in cases than controls, inferring an association with AD. Two missense mutations 
in PRSS45 are associated with protection against AD, p.I190L (rs58830807) and P130Q 
(rs58943210) however both are predicted to be benign. None of the genes aside from 
MEP1B have been directly linked to dementia.  
3.3 Polygenic risk scoring 
A 500kb region around the APOE gene containing 227 variants was excluded from the 
analysis to identify effects independent of APOE. The predictive accuracy of each tested 
model is given in Table 4, denoted by area under the curve (AUC), with 95% confidence 
intervals. The APOE ε4 allele alone has 71.8% accuracy in discriminating between cases 
and controls, however this is a poor fit model. Other covariates ε2, age, sex and GWAS 
greatly increase the predictive power 83.0%. In total 3,268 variants were utilised to score risk 
of developing AD using the best fit model, which had a predictive accuracy of 83.8% when 
combined with all covariates as predictors. The addition of PRS only increased this accuracy 
by 0.8%, which is similar to improvements seen in other studies. There is overlap between 
scores for both groups, however on average scores were higher for cases. Mean scores for 
AD cases were 3.6x10-4 compared to 2.7x10-4 for control samples.  
3.4 Screening for familial mutations 
Samples were screened for mutations in fEOAD genes to remove any non-sporadic cases. A 
total of 6 coding variants were found in APP (1), PSEN1 (1) and PSEN2 (4), shown in Table 
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except two identified as missense. PSEN1 p.E318G (rs17125721) was classified as a risk 
modifier but not pathogenic, found in 5 cases and 1 control sample. PSEN2 p.S130L 
(rs63750197) was previously identified as possibly damaging in silico with unclear 
pathogenicity, present in 1 case and 1 control. Both SNPs were predicted to be deleterious 
depending on the transcript. However, no causative or fully penetrant pathogenic mutations 
were observed in these genes, confirming that these samples are representative of sporadic 
AD. 
Other known neurologic genes were also screened for potential pathogenic mutations to 
identify genetic overlap between sporadic LOAD and other neurodegenerative diseases 
(Table 6). Mutations in Parkinson’s genes LRRK2, PARK2 and PINK1 appear to have some 
possibly damaging consequences on the proteins. PARK2 p.R275W (rs34424986) is very 
rare and present in 1 AD case and 1 control sample with mild cerebral amyloid angiopathy 
and presence of an unspecified dementia. SIFT/Polyphen2 predictions both indicate a 
potentially deleterious effect of this mutation. Variant p.P246L (rs149953814) was also found 
in 1 case and control, both also presenting with mild non-amyloid small vessel disease. 
Samples were heterozygous for both variants.  
Previously uncharacterised mutations were found in CHMP2B and LRRK2. The frameshift 
variant in CHMP2B was seen in a healthy control and an individual with AD. The LRRK2 
mutation was heterozygous in a sample of each phenotype and results in a p.L1271P 
change. PRNP p.M129V (rs1799990) has previously been implicated as a risk factor for 
prion disease, here however it is observed in an equal number of case and controls, 
suggesting no effect in AD.  
3.5 Association analyses of known neurologic genes 
Following on from this, genes were selected based on whether they had been linked to AD 
or other neurological diseases. Direct functionality was inferred from data filtered for coding 
variants only. A total of 76,640 variants were annotated as coding mutations, with 219 
variants in 35 of the selected genes. Association and burden analyses were performed as 
before on the subset of variants. No coding variants were identified in AD genes HLA-DRB1, 
HLA-DRB5 and MEF2C or the other neurologic genes MAPT and TARDBP.  
We performed single variant association on all 219 variants in the selected genes. No 
variants reached genome-wide or suggestive levels of significance as identified by a logistic 
regression test with correction for covariates. The most significant associations (P<0.05) are 
listed in Table 7. Results for all 219 variants are shown in supplementary Table S2.  
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variants are present, with 2 suggesting increased risk (OR>1) and 2 showing a protective 
effect (OR<1). ABCA7 rs3752234 and rs3752237 are both synonymous mutations that 
increase risk more than 2-fold. SLC24A4 synonymous SNP (rs7144273) also showed strong 
effects in the risk direction (OR=1.63, P=0.018).  
The majority of variants appear to be exhibiting a protective effect as indicated by the odds 
ratios, as they were observed more frequently in control samples. LRRK2 p.M1646T 
(rs35303786) missense is predicted as benign, however it is found in a greater frequency in 
control samples (OR=0.14, P=0.018). We calculated gene-based burden using a SKAT-O 
test to provide greater statistical power than that of a single-marker test (Table 8). Both sets 
of familial genes did not appear to exhibit any burden on LOAD. Burden analysis revealed 
two significant associations; APOE and CLU were the only genes to reach significance 
(P<0.05). However, they would not pass Bonferroni correction (P=0.0014). Five variants in 
CLU contributed to the effect seen, which was corrected for age, sex and APOE ε4 status. 
Two of these variants were significant, synonymous variant rs9331939 and rs149859119 
(p.S16R), therefore they could be driving the signal in this gene.  
 
4. Discussion 
In this study, we initially investigated genetic association with LOAD using an exome-wide 
approach. Although the analyses did not find any significant associations when corrected for 
multiple testing, the sample size only provides enough power to detect common variant 
(MAF>5%) associations with an effect size above 2.2 with 80% certainty. Nonetheless, 
single variant analysis highlighted some interesting tentative associations which may merit 
further exploration.  
Burden analysis revealed a tentative association with PILRA, an inhibitory immunoglobulin 
receptor involved in regulating signal transduction in the immune system. This gene has 
previously been linked to AD via its interaction with paired activation receptor PILRB and 
GWAS hit ZCWPW1. It is expressed on myeloid cells and works with PILRB, which also 
associates with DAP12 and TREM2 [40]. PILRA SNP rs2405442 is in weak LD (r2=0.5) with 
GWAS SNP rs1476679, suggesting this signal is likely to be independent of the GWAS 
association. ZCWPW1 locus SNP rs1476679 was nominally associated with reduced PILRA 
levels [41]. This suggests a potential role for the gene in AD, highlighting the need for further 
investigation.  
Many of the remaining genes on the burden list are enzymes with serine/threonine activity or 
serine proteases, such as PRSS45, BCR, KLK2 and THNSL2. Efficient breakdown of 
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Dysfunction of the amyloid protein degradation pathway has been implicated in AD. None of 
these genes have been previously linked to AD. However in combination, enzymes 
regulating protein function and breakdown could play a greater role in disease and this too 
warrants further exploration.  
Multiple PRSS45 variants were observed, with two missense mutations found to be 
associated with AD, exerting a protective effect. However, functional predictions indicate that 
both polymorphisms are benign. This gene encodes a serine protease, part of a group of 
enzymes that cleave peptide bonds. PRSS45 SNPs were also highly associated when 
tested in burden. Missense variants TMEM260 p.A245S and AVPR1B p.K65N were both 
predicted to be damaging to the protein in silico and found more frequently in control 
samples. The function of TMEM260 is not clearly understood, whereas AVPR1B is a 
vasopressin receptor located in the anterior pituitary gland that stimulates ACTH release. 
AVPR1B SNP rs35369693 has been linked to mood disorders and found more frequently in 
affected females [42]. The mutation in MEP1B, known as meprin β is synonymous; recent 
proteomic studies have found that these metalloproteases can cleave APP, affecting Aβ 
levels [43,44]. While these associations are tentative, examination of other larger datasets 
could be worthwhile.  
PRS generated for individuals showed that, on average, scores were significantly higher in 
LOAD cases than controls, despite an overlap amongst the cohort. Using sex, age at death, 
APOE ε4 and ε2 allele counts and GWAS SNP genotypes as variables for prediction, the 
model was able to distinguish cases and control with 83.8% accuracy. A total of 3,268 
variants were used to predict disease risk. The presence of controls with high risk scores 
suggests that these individuals may have gone on to develop AD had they lived longer. The 
utility of PRS has already been demonstrated in AD, with individuals’ genetic risk profiles 
able to predict disease susceptibility with more than 80% accuracy [45]. However, there 
were controls with high PRS and no phenotypic changes indicative of dementia and also 
cases with low PRS. Although PRS can identify more of the genetic component of AD, this 
shows that there is still unexplained missing heritability.  
Mutations in familial AD genes, APP, PSEN1 and PSEN2 are rare but highly penetrant. 
Screening of these genes revealed no pathogenic variants and samples harbouring 
mutations were heterozygotes, confirming there were no familial EOAD cases amongst the 
BDR LOAD classified cases. Other neurologic familial genes were also screened for 
pathogenic mutations linked to related dementias. No known causative mutations were 
identified, however PARK2 p.R275W was predicted to be deleterious and has unknown 
pathogenicity in the PD mutation database. It produces an unusual distribution of parkin with 
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control sample, however, which suggests that it is likely benign and not pathogenic in nature. 
Previously uncharacterised mutations were identified in CHMP2B and LRRK2, with a 
frameshift variant in CHMP2B and a missense variant in LRRK2. The frameshift variant was 
only seen in one control sample, suggesting that it could be a sequencing artifact. LRRK2 
p.L1271P is present in a case and control sample so does not appear to segregate with 
disease. PRNP p.M129V has been highlighted as a risk factor for prion disease but appears 
not to be having any effect in AD.  
TREM2 mutation p.R47H was observed in 3 AD case samples which were heterozygotes. 
This variant can increase risk of developing AD by 2-3 fold [12,47]. DNA was available for 
these 3 samples and Sanger sequencing confirmed the presence of the variant in these 
subjects. No control samples harboured this variant. However, given the documented 
frequency of R47H (MAF=0.002) this cohort appears to have a greater MAF of 0.008. This 4-
fold greater frequency will be verified as the BDR sample set increases in size.  
Single variant association of all neurologic gene variants revealed several synonymous 
mutations to be nominally associated with AD at P<0.05. The majority of variants exerted 
effects in the protective direction with greater frequency in controls than case samples. Four 
ABCA7 variants were significantly associated at P<0.05 with 2 increasing risk and 2 being 
protective. Synonymous variants rs3752234 and rs3752237 increased AD risk more than 2-
fold, which is contradictory to previous findings [48,49], where the effects were protective. 
Conversely, rs4147915 and missense mutation rs3764645 p.E188G are protective. ABCA7 
p.E188G is predicted as tolerated and previously shown to have no effect on disease risk 
[48]. These findings need to be validated as the sample size increases. 
Missense variant LRRK2 p.M1646T was associated with protection against AD, but the 
amino acid substitution is predicted to be tolerated. However the mutation is known to 
increase risk of developing PD [50]. LRRK2 mutations have previously been linked to AD 
with PD risk variant p.R1628P found in greater frequencies in AD cases than controls [51]. 
The variant increased apoptosis and cell death in transfected human cell lines. Therefore, it 
is likely that genetic pleiotropy possibly occurs across several neurodegenerative diseases. 
LRRK2 is involved in autophagy and recycling proteins in the retrograde trafficking pathway. 
Mutations in this protein are associated with dendrite shortening in neurons, a possible 
cause of motor symptoms in PD [46]. With some shared clinical features, mutations in 
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Gene-based burden analysis in SKAT-O allowed adjustment to correct for the effect of age, 
sex and number of APOE ε4 alleles. Both AD and other neurologic familial genes did not 
exhibit any burden on LOAD. APOE and CLU were significant to P<0.05 but did not pass 
Bonferroni correction. Only SNP p.S16R in CLU was significantly associated in single variant 
testing, indicating that this is driving the signal.  
 
5. Conclusion 
Although other familial neurologic genes did not show any burden on LOAD, an individual 
missense variant in LRRK2 was tentatively associated; preliminary exploration of the data 
has indicated that genetic pleiotropy is likely to play a role in diseases with overlapping 
features. LRRK2 is involved in PD, yet few studies have investigated its role in other 
dementias.  
Exome-wide analysis has revealed a significant burden of PILRA variants on AD. Previous 
studies have identified a possible link with AD via GWAS hit ZCWPW1 and paired receptor 
PILRB which associates with DAP12 and TREM2. PILRA and PILRB function may be co-
regulated and therefore further investigation should involve looking at both genes in AD. 
Limitations in power have made it difficult to find many significant associations, but with on-
going data collection, the sample size will increase to address this issue. However, using an 
exome sequencing approach it has been possible to detect rare variants with greater effect 
sizes, which previous GWAS did not permit.  
Supplementary Information 
Supplementary Table S1. Summary data of all case and control samples used for analysis. 
Supplementary Table S2. Variants found in AD-related genes in 129 LOAD cases and 53 
controls.  
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Table 1. Demographics of LOAD cases and cognitively normal samples in the BDR cohort. The cohort contains individuals from multiple centres. 
Sample demographics are divided into (a) LOAD cases and (b) cognitively normal controls for each centre and overall. Information provided includes: Number 
and percentage of case or control individuals per centre [N (%)], Mean age at death with standard deviation [Mean AAD (+SD)], Number and percentage of 
case or control females per centre [Females (%)], Number and percentages of case or control individuals harbouring at least one APOE ε4 allele [APOE ε4+ 
(%)], APOE ε4 minor allele frequency [APOE ε4 MAF], Number and percentage of case or control individuals with two ε4 alleles [APOE ε4ε4 (%)].  











Bristol 7 (41.2) 86.0 (+6.1) 4 (57.1) 7 (100.0) 0.43 1 (14.3) 
London 29 (58.0) 82.0 (+7.4) 18 (62.1) 17 (58.6) 0.35 4 (13.8) 
Manchester 27 (81.8) 80.8 (+8.2) 12 (44.4) 18 (66.7) 0.46 7 (25.9) 
Newcastle 15 (78.9) 85.1 (+8.3) 8 (53.3) 10 (66.7) 0.39 2 (13.3) 
Oxford 54 (81.8) 83.1 (+8.9) 28 (51.9) 33 (61.1) 0.4 9 (16.6) 
All 132 (71.4) 82.5 (+8.4) 70 (53.0) 85 (64.4) 0.4 23 (17.3) 
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Bristol 10 (58.8) 84.5 (+7.5) 4 (40.0) 6 (60.0) 0.15 0 (0.0) 
London 21 (42.0) 83.0 (+0.0) 11 (52.4) 5 (23.8) 0.12 0 (0.0) 
Manchester 6 (18.2) 87.8 (+5.0) 4 (66.7) 0 (0.0) 0 0 (0.0) 
Newcastle 4 (21.1) 86.3 (+4.6) 1 (25.0) 1 (25.0) 0.13 0 (0.0) 
Oxford 12 (18.2) 86.4 (+7.8) 7 (58.3) 1 (8.3) 0.04 0 (0.0) 
All 53 (28.6) 85.9 (+6.5) 27 (50.9) 13 (24.5) 0.09 0 (0.0) 
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Table 2. Burden analysis results for exome-wide analysis. Burden analysis of all genes was performed using a C-alpha test without correction for 
covariates. The results shown are significant to P<0.001. Information includes: Gene name [Gene], mRNA [mRNA ID], chromosomal position in genome build 
hg19 [Position], number of variants contributing to the signal [Number of Variants], significance [P-value].  
 




PILRA NM_013439 7:99971313-99997454 5 3.40E-05 
PRSS45 NM_199183 3:46783959-46785453 4 5.92E-05 
THNSL2 NM_001244676 2:88470874-88485392 12 1.49E-04 
KLK2 NM_001002231 19:51376837-51381777 8 1.96E-04 
STOX2 NM_020225 4:184930646-184932631 8 2.42E-04 
SEC31A NM_001077206 4:83740163-83803115 23 3.58E-04 
PRSS42 NM_182702 3:46875258-46875258 1 3.81E-04 
HAS3 NM_138612 16:69143481-6915 2391 4 4.09E-04 
KLRF2 NM_001190765 12:10041364-10048327 5 5.08E-04 
SLC22A2 NM_003058 6:160638357-160677614 9 5.48E-04 
GRIK2 NM_001166247 6:102134022-102516260 10 5.77E-04 
TRDMT1 NM_004412 10:17194026-17243638 12 6.86E-04 
FAM136A NM_032822 2:70528601-70529205 5 7.25E-04 
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APOC1 NM_001645 19:45419414-45422561 2 8.28E-04 
HAS3 NM_001199280 16:69143481-69143816 3 8.52E-04 
TMIE NM_147196 3:46742941-46751229 3 8.84E-04 
BCR NM_004327 22:23523602-23657604 24 8.96E-04 
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Table 3. Top results shown for exome-wide association analysis of non-singleton variants. Logistic regression results are shown for variants 
associated with AD (P<0.001). Significance values were adjusted for the covariates sex, age at death and number of APOE ε4 alleles. Information includes: 
Gene containing the variant [Gene], Variant RSID [Variant], Position in hg19 [Position], allelic change [Allele], MAF in ExAC database [ExAC MAF], MAF and 
counts in cases and controls [MAF (Count)], Significance of association [P-value], Size of effect with 95% confidence intervals [Odds Ration (95% CI)], coding 
consequence [Consequence], amino acid change in protein [Protein Change], predicted consequence of change using SIFT and Polyphen2 [Functional 
Prediction]. * indicates discrepancy between SIFT and Polyphen2 predictions. 
 













TCEB3 rs2235541 1:24077451 C>T 0.09 0.06 (15) 0.15 (16) 2.44E-04 0.15 (0.06-0.42) Missense T145M Deleterious * 
AVPR1B rs35369693 1:206224635 G>C 0.04 0.05 (13) 0.16 (17) 8.44E-04 0.21 (0.09-0.53) Missense K65N 
Probably 
damaging  
PRSS45 rs58830807 3:46783959 T>C 0.18 0.09 (23) 0.24 (25) 1.41E-04 0.21 (0.1-0.47) Missense I190V Tolerated  
PRSS45 rs58943210 3:46784467 G>A 0.18 0.09 (23) 0.23 (24) 2.67E-04 0.23 (0.1-0.5) Missense P130L Tolerated  
SEC31A rs10025654 4:83795806 C>T 0.51 0.4 (105) 0.58 (62) 5.29E-04 0.38 (0.22-0.66) Synonymous R199 
No functional 
change 
ITPR3 rs35506178 6:33658780 C>T 0.04 0.03 (7) 0.08 (9) 8.50E-04 0.12 (0.03-0.41) Synonymous A2373 
No functional 
change 
PCLO rs2877 7:82764425 G>C 0.75 0.26 (69) 0.44 (47) 4.88E-04 0.36 (0.2-0.64) Missense S814T Benign 
CPA1 rs968404 7:130022041 C>T 0.13 0.14 (38) 0.25 (26) 4.67E-04 0.26 (0.12-0.55) Synonymous Y158 
No functional 
change 
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NTN4 rs17851048 12:96077312 C>T 0.22 0.2 (53) 0.41 (43) 2.18E-04 0.31 (0.17-0.58) Synonymous A452 
No functional 
change 
TMEM260 rs17776256 14:57075920 G>T 0.12 0.08 (20) 0.18 (19) 4.96E-04 0.21 (0.09-0.5) Missense A245S/T 
Probably 
damaging  
UBR7 rs2286653 14:93673655 G>A 0.15 0.05 (12) 0.16 (17) 6.21E-04 0.17 (0.06-0.47) Missense A7T Tolerated  
IGFALS rs17559 16:1841033 G>A 0.15 0.07 (18) 0.2 (21) 8.34E-04 0.26 (0.12-0.57) Synonymous Y500 
No functional 
change 
MEP1B rs173032 18:29795076 C>T 0.68 0.41 (107) 0.25 (27) 6.48E-04 3.08 (1.61-5.89) Synonymous S537 
No functional 
change 
LRRC8E rs2042919 19:7963949 A>G 0.23 0.25 (67) 0.36 (38) 6.45E-04 0.32 (0.17-0.62) Missense E181G Tolerated  
LRRC8E rs3745382 19:7964727 G>A 0.21 0.26 (68) 0.36 (38) 6.60E-04 0.32 (0.17-0.62) Synonymous E440 
No functional 
change 
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Table 4. Predictive accuracy model for 132 AD cases versus 53 controls. Different predictors were compared for their accuracy in predicting risk of 
developing AD. APOE ε4 and ε2 alleles, sex, age at death and genotypes for 19 of the GWAS SNPs were used as predictors. PRS were constructed using 
independent variants associated with AD at a threshold of P<0.05, excluding the APOE region +500kb and the GWAS variants. Nagelkerke’s R
2
 expresses 
the proportion of variance explained by the model, with the largest R
2
 value indicating the best model. Area under the Receiver Operating Characteristic curve 
(AUC) is a measure of predictive accuracy, which quantifies the overall ability to discriminate between case and control individuals. The Hosmer-Lemeshow 





Area under ROC 
curve (AUC) 
AUC 95% CI 
Hosmer-Lemeshow 
Test P-value 
ε4 0.086 0.718 0.642 – 0.794 0.001 
ε4 + ε2 0.215 0.734 0.660 – 0.809 0.347 
ε4 + ε2 + Sex + Age 0.223 0.742 0.668 – 0.816 0.891 
ε4 + ε2 + Sex + Age + GWAS 0.366 0.830 0.770 – 0.891 0.816 
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Table 5. Coding variants found in familial AD genes APP, PSEN1 and PSEN2 in LOAD cohort. Coding variants present in BDR samples in familial AD 
genes APP (1), PSEN1 (1) and PSEN2 (4) are catalogued here with a prediction of the functional consequences of each mutation. * indicates discrepancy 
between SIFT and Polyphen2 predictions. 









APP rs148888161 21:27264121 G>A 0.002 0.007 (2) 0.009 (1) Synonymous G708 No functional change 
PSEN1 rs17125721 14:73673178 A>G 0.015 0.015 (5) 0.009 (1) Missense E318G Probably damaging * 
PSEN2 
rs11405 1:227069677 C>T 0.76 0.189 (50) 0.198 (21) Synonymous A23 No functional change 
rs1046240 1:227071525 T>C 0.49 0.439 (116) 0.396 (42) Synonymous H87 No functional change 
rs63750197 1:227073271 C>T 0.0006 0.004 (1) 0.009 (1) Missense S130L Possibly damaging * 
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Table 6. Cataloguing pathogenic mutations in other familial neurologic genes. Variants in genes previously linked to other neurologic disorders were 
investigated for known pathogenic mutations. Only mutations causing an amino acid change are listed here therefore synonymous mutations were excluded. 
Clinical significance was determined from information available online from AD&FTD and PD mutation databases. ‘NA’ indicates that no functional or clinical 
information or MAF was available. * indicates discrepancy between SIFT and Polyphen2 predictions. 












CHMP2B chr3:87299112 3:87299112 ATGAC>A NA 0.003 (1) 0.009 (1) Frameshift NA NA NA 










LRRK2 chr12:40697972 12:40697972 A>T NA 0.003 (1) 0.009 (1) Missense L1271P NA NA 
















PINK1 rs1043424 1:20977000 A>C 0.297 0.311 (95) 0.255 (28) Missense N521T Tolerated 
Not 
pathogenic 
PRNP rs138688873 20:4680095 
229-
252del24 
0.019 0.003 (1) 0.009 (1) 
In-frame 
deletion 
77-84del NA NA 
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Table 7. Single-SNP association results for variants in known neurological genes with AD. Association results for single variants with Alzheimer's 
disease, corrected for sex, age at death and APOE ε4 allele count. The variants significant to P<0.05 are listed here with predicted functional consequence. * 
indicates discrepancy between SIFT and Polyphen2 predictions. 













LRRK2 rs35303786 12:40713899 T>C 0.01 0.01 (3) 0.05 (5) 0.018 0.14 (0.03-0.71) Missense M1646T Tolerated 
SLC24A4 rs7144273 14:92920371 T>C 0.50 0.5 (153) 0.39 (43) 0.044 1.63 (1.01-2.63) Synonymous P319 No 
functional 
change 
ABCA7 rs3764645 19:1042809 A>G 0.48 0.42 (127) 0.6 (66) 0.001 0.43 (0.26-0.72) Missense E188G Tolerated 
ABCA7 rs3752234 19:1047002 G>A 0.55 0.51 (157) 0.39 (43) 0.004 2.06 (1.25-3.4) Synonymous A608 No 
functional 
change 
ABCA7 rs3752237 19:1047161 G>A 0.68 0.46 (142) 0.29 (32) 0.001 2.42 (1.46-4.02) Synonymous G617 No 
functional 
change 
ABCA7 rs4147915 19:1049305 C>A 0.18 0.11 (34) 0.2 (22) 0.010 0.4 (0.2-0.8) Synonymous V807 No 
functional 
change 
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Table 8. Burden analysis results for known neurodegenerative genes. Burden analysis results from SKAT-O are shown here for (a) Familial AD genes; 
(b) LOAD-specific genes from GWAS and NGS studies; (c) Familial genes in other neurodegenerative diseases. The total numbers of markers within genes 
are shown, together with number of coding variants and the number of markers used for burden testing. The p-value signifies the association of multiple 












APP 10 1 1 0.61 
PSEN1 4 2 2 1.00 
PSEN2 7 4 4 0.83 
(b) LOAD 
genes 
ABCA7 48 28 28 0.59 
APOE 4 4 4 0.06 
BIN1 17 6 6 0.25 
CASS4 11 7 7 0.32 
CD2AP 9 4 4 0.58 
CD33 4 4 4 0.77 
CELF1 4 3 3 1.00 
CLU 5 5 5 0.02 
CR1 17 9 9 0.31 
EPHA1 15 10 9 0.14 
FERMT2 7 3 3 0.86 
INPP5D 6 2 2 0.54 
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NME8 16 8 8 1.00 
PICALM 11 3 3 0.63 
PTK2B 35 17 16 0.44 
RIN3 11 9 9 1.00 
SLC24A4 22 8 8 0.69 
SORL1 29 16 16 0.05 
TREM2 4 4 3 0.23 





C9orf72 11 4 4 0.66 
CHMP2B 5 3 3 0.24 
FUS 4 2 2 1.00 
GRN 9 3 3 0.84 
LRRK2 29 20 20 0.12 
PARK2 13 5 5 0.27 
PARK7 6 1 1 0.33 
PINK1 9 4 4 0.88 
PRNP 7 4 4 0.35 
SNCA 8 2 2 0.15 
VCP 6 2 2 0.34 
 
 
